<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Pharmacogenomics of Bladder Cancer</title>
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css">
<style>
body {
  font-family: "Arial", sans-serif;
  margin: 0;
}

/* Sidebar */
.sidenav {
  height: 100%;
  width: 200px;
  position: fixed;
  top: 0;
  left: 0;
  background: linear-gradient(to bottom, #FFE53B 0%, #00FFFF 100%);
  overflow-x: hidden;
  transition: 0.5s;
  padding-top: 30px;
  z-index: 2;
}

.sidenav a, .dropdown-btn {
  padding: 6px 8px 6px 16px;
  text-decoration: none;
  font-size: 17px;
  color: black;
  display: block;
  border: none;
  background: none;
  width: 80%;
  text-align: left;
  cursor: pointer;
  outline: none;
}

.sidenav a:hover, .dropdown-btn:hover {
  color: #f1f1f1;
}

.dropdown-container {
  display: none;
  background-color: white;
  padding-left: 8px;
}

.active {
  color: grey;
}

.fa-caret-down {
  float: right;
  padding-right: 8px;
}

/* Toggle Button */
#toggleBtn {
  position: fixed;
  top: 3px;
  left: 210px;
  font-size: 20px;
  cursor: pointer;
  background-color: #333333;
  color: white;
  border: none;
  padding: 10px;
  border-radius: 5px;
  z-index: 3;
  transition: left 0.5s;
}

/* Header */
.header {
  padding: 23px;
  text-align: center;
  background: #1abc9c;
  color: white;
  font-size: 30px;
  margin-left: 200px;
  transition: margin-left 0.5s;
}

/* Main Content */
.main-content {
  margin-left: 200px;
  padding: 20px;
  transition: margin-left 0.5s;
}

/* Table Styling */
table {
  font-family: Arial, sans-serif;
  border-collapse: collapse;
  width: 90%;
  margin-left: auto;
  margin-right: auto;
}

th, td {
  border: 1px solid #cce5ff;
  text-align: left;
  padding: 9px;
}

tr:nth-child(odd) {
   background: linear-gradient(to bottom, #ffff66 0%, #ff9966 100%);
}
</style>
</head>

<body>

<div class="sidenav" id="mySidenav">
  <a href="./../factlens_main.html">&laquo; Main</a>
  <button class="dropdown-btn">Incidence <i class="fa fa-caret-down"></i></button>
  <div class="dropdown-container">
    <a href="in_both.html">Both Sexes</a>
    <a href="in_male.html">Males</a>
    <a href="in_female.html">Females</a>
  </div>
  <button class="dropdown-btn">Mortality <i class="fa fa-caret-down"></i></button>
  <div class="dropdown-container">
    <a href="m_both.html">Both Sexes</a>
    <a href="m_male.html">Males</a>
    <a href="m_female.html">Females</a>
  </div>
  <button class="dropdown-btn">Prevalence <i class="fa fa-caret-down"></i></button>
  <div class="dropdown-container">
    <a href="p_both.html">Both Sexes</a>
    <a href="p_male.html">Males</a>
    <a href="p_female.html">Females</a>
  </div>
  <a href="diagnosis.html">Diagnosis</a>
  <button class="dropdown-btn">Biomarkers <i class="fa fa-caret-down"></i></button>
  <div class="dropdown-container">
    <a href="biomarker.html">Biomarker</a>
    <a href="cyto.html">Cytogenetics</a>
    <a href="pharm.html">Pharmacogenomics</a>
  </div>
  <a href="treatment.html">Treatment</a>
  <a href="drug.html">Drugs</a>
  <a href="nutri.html">Nutrigenomics</a>
  <a href="gene.html">Genes</a>
  <a href="poly.html">Polymorphisms</a>
  <a href="path.html">Signalling Pathways</a>
 
</div>

<button id="toggleBtn"> Menu</button>

<div class="header" id="header">
  <h1>Pharmacogenomics of Bladder Cancer</h1>
</div>

<div class="main-content" id="mainContent">

<!-- PGx Table -->
<table>
<thead>
  <tr>
    <th width="140">Pharmacogenomic Factor	</th>
    <th width="150">Gene</th>
    <th width="150">SNP/Mutation</th>  
	<th width="250">Drug and Dosage</th>
	<th width="100">Stage of Bladder Cancer</th>
	<th width="100">Molecular Function</th>
	<th width="260">Significance/Inference</th>
	  </tr>
  <tr>
      <td>DNA Repair	</td>
    <td>ERCC1</td>	
	<td>Expression level</td>
	<td>Cisplatin (70-100 mg/mÂ² IV q3wk, with/without gemcitabine)	</td>
    <td>Advanced/metastatic	</td>
<td>Nucleotide excision repair	</td>
<td>High ERCC1 expression linked to cisplatin resistance and shorter survival; low ERCC1 = better response	
<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC3904434/">(1)</a></td>
  </tr>
  <tr>
      <td >Growth Factor Receptor		</td> 
	<td >FGFR3	</td>
	<td >Activating mutations	</td>
    <td>TYRA-300 90 mg PO daily (investigational; for FGFR3-mutant)	</td>
   	<td>Metastatic/advanced, FGFR3-mutant	</td>
<td>Receptor tyrosine kinase signaling		</td>
<td>FGFR3 mutations sensitize to FGFR inhibitors (e.g., TYRA-300); improved tolerability over pan-FGFR drugs	
	<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6171176/">(2)</a></td>
  </tr><tr><tr>
      <td >Growth Factor Receptor		</td> 
	<td >EGFR	</td>
	<td >Overexpression</td>
    <td>EGFR inhibitors (e.g., gefitinib 250 mg PO daily, erlotinib 150 mg PO daily)</td>
   	<td>Advanced/metastatic, cell line	</td>
<td>Receptor tyrosine kinase signaling	</td>
<td>High EGFR expression correlates with sensitivity to EGFR-targeted drugs	<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC6171176/">(2)</a></td>
  </tr><tr>
   
    <td >Cell Cycle Regulation		</td>  
	<td >CCNA2, CCNB1, CDK1, PLK1, AURKA, AURKB, FOXM1, CALML5		</td>  
	<td >Overexpression	</td>
    <td>Volasertib (BI 6727) (investigational) 300 mg IV every 3 weeks		</td>
    <td>Advanced/metastatic, experimental		</td>
	<td>Cell cycle progression, mitosis, proliferation	</td>
	<td>Overexpression linked to tumor progression; potential targets for novel therapies	
<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507096/">(3)</a></td>
  
  </tr><tr>	
  <td >Immune Checkpoint	</td>
    <td >PD-L1	</td> 
    <td>Expression level	</td>
	<td>Avelumab 800 mg IV every 2 weeks; <br><br><br>Pembrolizumab 200 mg IV every 3 weeks		</td>
<td>Advanced/metastatic, maintenance		</td>
<td>Immune evasion		</td>
<td>High PD-L1 expression may predict better response to checkpoint inhibitors<a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11507096/">(3)</a></td>
  </tr>
          </tbody>
</table>

</div>

<script>
// Dropdowns
var dropdown = document.getElementsByClassName("dropdown-btn");
for (var i = 0; i < dropdown.length; i++) {
  dropdown[i].addEventListener("click", function() {
    this.classList.toggle("active");
    var dropdownContent = this.nextElementSibling;
    if (dropdownContent.style.display === "block") {
      dropdownContent.style.display = "none";
    } else {
      dropdownContent.style.display = "block";
    }
  });
}

// Toggle Sidebar
var toggleBtn = document.getElementById("toggleBtn");
var sidenav = document.getElementById("mySidenav");
var header = document.getElementById("header");
var mainContent = document.getElementById("mainContent");

function toggleSidebar() {
  if (sidenav.style.width === "0px") {
    sidenav.style.width = "200px";
    header.style.marginLeft = "200px";
    mainContent.style.marginLeft = "200px";
    toggleBtn.style.left = "210px";
  } else {
    sidenav.style.width = "0px";
    header.style.marginLeft = "0px";
    mainContent.style.marginLeft = "0px";
    toggleBtn.style.left = "10px";
  }
}

// Auto close after 3 sec
setTimeout(function() {
  toggleSidebar();
}, 3000);

toggleBtn.onclick = toggleSidebar;
</script>

</body>
</html>
